Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) CEO Sells $5,133,500.00 in Stock

Posted by on Sep 17th, 2026

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) CEO David Meeker sold 50,000 shares of the firm’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $102.67, for a total value of $5,133,500.00. Following the transaction, the chief executive officer owned 239,258 shares in the company, valued at $24,564,618.86. This trade represents a 17.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Rhythm Pharmaceuticals Price Performance

RYTM stock opened at $98.01 on Thursday. Rhythm Pharmaceuticals, Inc. has a 1-year low of $74.50 and a 1-year high of $122.20. The firm has a fifty day moving average price of $107.78 and a two-hundred day moving average price of $97.19. The firm has a market cap of $6.72 billion, a price-to-earnings ratio of -31.51 and a beta of 1.97.

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.08. Rhythm Pharmaceuticals had a negative net margin of 85.59% and a negative return on equity of 159.87%. The business had revenue of $71.25 million during the quarter, compared to analyst estimates of $67.66 million. During the same period in the previous year, the business posted ($0.75) EPS. The company’s quarterly revenue was up 46.9% on a year-over-year basis. As a group, analysts expect that Rhythm Pharmaceuticals, Inc. will post -2.86 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on RYTM shares. Citigroup restated a “market outperform” rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday, August 5th. Royal Bank Of Canada upped their price target on shares of Rhythm Pharmaceuticals from $141.00 to $155.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. JPMorgan Chase & Co. increased their price objective on shares of Rhythm Pharmaceuticals from $145.00 to $146.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. National Bank Financial set a $160.00 target price on shares of Rhythm Pharmaceuticals in a research note on Wednesday, August 5th. Finally, Stifel Nicolaus set a $133.00 target price on shares of Rhythm Pharmaceuticals in a research note on Monday, June 15th. Sixteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $140.67.

Check Out Our Latest Stock Analysis on RYTM

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in Rhythm Pharmaceuticals during the second quarter valued at about $683,601,000. Primecap Management Co. CA purchased a new position in shares of Rhythm Pharmaceuticals in the second quarter worth approximately $351,838,000. Geode Capital Management LLC raised its holdings in shares of Rhythm Pharmaceuticals by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 1,375,729 shares of the company’s stock valued at $147,283,000 after acquiring an additional 12,900 shares during the period. Westfield Capital Management Co. LP raised its holdings in shares of Rhythm Pharmaceuticals by 18.5% during the fourth quarter. Westfield Capital Management Co. LP now owns 1,267,158 shares of the company’s stock valued at $135,637,000 after acquiring an additional 198,154 shares during the period. Finally, Capital Research Global Investors lifted its position in shares of Rhythm Pharmaceuticals by 64.7% in the 4th quarter. Capital Research Global Investors now owns 985,086 shares of the company’s stock valued at $105,444,000 after acquiring an additional 386,839 shares in the last quarter.

Rhythm Pharmaceuticals Company Profile

(Get Free Report)

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases of obesity and related metabolic disorders. The company’s research is centered on the melanocortin-4 receptor (MC4R) pathway, which plays an important role in regulating hunger and energy balance.

Rhythm’s primary product is IMCIVREE (setmelanotide), an MC4R agonist. In the United States, IMCIVREE is approved for chronic weight management in adults and children at least 2 years old with obesity and certain genetically confirmed conditions affecting the MC4R pathway, including pro-opiomelanocortin, proprotein convertase subtilisin/kexin type 1 and leptin receptor deficiencies, as well as Bardet-Biedl syndrome.

Read More

Insider Buying and Selling by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.